Literature DB >> 2303492

Incorporation of 2-halogeno-2'-deoxyadenosine 5-triphosphates into DNA during replication by human polymerases alpha and beta.

P Hentosh1, R Koob, R L Blakley.   

Abstract

Extension of synthetic primers by purified human polymerase alpha (Hpol alpha) with the (+)-strand of M13mp18 DNA as template encounters numerous specific pause sites on the M13 template. Some of these are regions of template secondary structure, at others the template codes for incorporation of the same base in multiple consecutive positions, but at some the responsible feature in the sequence is not obvious. 2-Chloro-dATP (CldATP) substitutes efficiently for dATP in such chain extension, with 2-chloroadenine (ClA) incorporation into many positions coding for A. However, there are more sites where extension is interrupted than with all four normal nucleotide substrates, particularly (but not exclusively) at template secondary structure and sites of multiple consecutive ClA insertion. DNA synthesis from normal substrates by Hpol beta in this system shows less frequent and less marked pauses, but with CldATP substituted for dATP chain extension is limited because of marked slowing of extension at sites of multiple consecutive ClA insertion. With either polymerase, the rate of extension is decreased even more at such regions when bromo-dATP is used as substrate. Some misincorporation of ClA instead of G or T can occur at certain sites in absence of the corresponding normal substrate, but misincorporation as C is rare. CldATP is a very weak inhibitor of chain extension by Hpol alpha, but a somewhat better inhibitor of Hpol beta. These results may account in part for the inhibition of DNA synthesis in cells exposed to 2-chlorodeoxyadenosine or 2-bromodeoxyadenosine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2303492

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  ABC transporters and their role in nucleoside and nucleotide drug resistance.

Authors:  Yu Fukuda; John D Schuetz
Journal:  Biochem Pharmacol       Date:  2012-01-20       Impact factor: 5.858

2.  Effects of 2-chloroadenine substitution in DNA on restriction endonuclease cleavage reactions.

Authors:  P Hentosh; J C McCastlain
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

3.  Induction of an apoptotic program in cell-free extracts by 2-chloro-2'-deoxyadenosine 5'-triphosphate and cytochrome c.

Authors:  L M Leoni; Q Chao; H B Cottam; D Genini; M Rosenbach; C J Carrera; I Budihardjo; X Wang; D A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

Review 4.  Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.

Authors:  H M Bryson; E M Sorkin
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

5.  Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues.

Authors:  Lisa S Chen; William Plunkett; Varsha Gandhi
Journal:  Leuk Res       Date:  2008-04-22       Impact factor: 3.156

6.  2-Chloro-2'-deoxyadenosine monophosphate residues in DNA enhance susceptibility to 3'-->5' exonucleases.

Authors:  P Hentosh; P Grippo
Journal:  Biochem J       Date:  1994-09-01       Impact factor: 3.857

7.  2-Chloro-2'-deoxyadenosine: alteration of DNA:TATA element binding protein (TBP) interactions.

Authors:  Theodore T Foley; Patricia Hentosh; D Eric Walters
Journal:  J Mol Model       Date:  2003-11-11       Impact factor: 1.810

8.  2 chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms.

Authors:  R A Nagourney; S S Evans; J C Messenger; Y Z Su; L M Weisenthal
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

Review 9.  New insights into the synergism of nucleoside analogs with radiotherapy.

Authors:  Michael W Lee; William B Parker; Bo Xu
Journal:  Radiat Oncol       Date:  2013-09-26       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.